Company intelligence / Profile preview
Aventi
South Koreaaventi.co.kr ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Aventi is conducting a Phase 2a study for AVTR101 for Sarcopenia. The randomized, double-blind, placebo-controlled, multi-center trial is ongoing. Their lead candidate AVTR101 was discovered through high-throughput phenotypic screening and increases muscle mass and improves exercise performance.[6]
- Therapeutic areas
- Metabolic DisordersOncologyOther
- Modalities
- Small moleculesMyokine (protein)Metabolites
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
JD BioscienceKRIBB (Korea Research Institute of Bioscience and Biotechnology)
Beyond the preview
Go deeper on Aventi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aventi.